Day: September 7, 2022

Posted on

Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer

WALTHAM, Mass. and SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer. Dr. Lowry brings over 20 years of broad clinical expertise in the design and execution of early to late-stage clinical programs to Zenas, where he will lead the company’s global clinical, medical affairs, and pharmacovigilance functions.

“We are delighted to welcome Dr. Lowry to Zenas at this pivotal time for the company as we commence two phase three registration trials for our lead product candidate, obexelimab, in the fourth quarter of this year and initiate first-in-human clinical trials for multiple pipeline programs,” said Hua Mu, M.D., Ph. D, Chief Executive Officer at Zenas. “Dr. Lowry’s proven leadership, broad clinical development background, and extensive global clinical trial experience will further strengthen our ability to execute on our mission to transform the lives of patients with unmet medical needs by bringing best-in-class immune-based therapies to patients.”

Dr. Simon Lowry added, “There are many patients with autoimmune and rare diseases in need of effective new treatment options. The deeply experienced and talented Zenas team has made impressive progress advancing the company’s pipeline in a very short period of time, and I look forward to leading the ongoing advancement of Zenas’ clinical programs through commercialization while further expanding the company’s pipeline of innovative programs.”

Dr. Lowry is a medical doctor with 20 years of experience at large and emerging pharmaceutical and biotechnology companies directing successful development programs, leading clinical and medical affairs teams, and interacting with regulatory agencies across multiple areas of medicine, including rheumatology, immunology, and ophthalmology. Prior to joining Zenas, Dr. Lowry was Chief Medical Officer at Kinevant Science, a clinical-stage biopharmaceutical company focused on treating rare inflammatory and autoimmune diseases. Dr. Lowry was previously Head of Immunology R&D at Roivant Sciences, leading all development stage immunology assets into clinical development, and served as a key member of the leadership team. He also served as Chief Medical Officer at Sun Pharma North America, where he was responsible for four branded therapeutic areas (Immunology & Dermatology, Ophthalmology, Neurology and Oncology), and led all aspects of development and medical functions (including clinical development, medical information, field medical, HEOR, publications / medical communications, and operations). Early in his career, he worked at Novartis, where he served as Vice President, Global Medical Affairs Franchise Head, Immunology & Dermatology, and Pfizer, where he served in roles of increasing responsibility, including as Vice President, Oncology Medical Affairs Group Leader.

Prior to his pharmaceutical/ biotechnology career, Dr. Lowry practiced internal medicine at various institutions in the UK and Australia. He received his BA from Trinity Hall, Cambridge University, UK and his MB BChir medical degree from Cambridge University School of Clinical Medicine.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations in the US and China, Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Posted on

Election of Directors of Sakrand Sugar Mills Limited

Karachi, Sakrand Sugar Mills Limited informed Pakistan Stock Exchange that the seven members have filed with the company offering themselves for election as Directors of the company at their Annual General Meeting held to be held on September 14, 2022 at Karachi.

Sakrand Sugar Mills Limited was incorporated in Pakistan as a Public Limited Company on March 02, 1989. The principal business of the company is to manufacture and sell white sugar.

The company is listed on Pakistan Stock Exchange and the total numbers of shares of the Company are 44,616,000. The Earnings per shares of the Company was (13.43) in 2020 which was 3.51 in 2019. Their Profit after Tax was (599,246,000) in 2020 which was 156,649,000 in 2019.

Posted on

Transaction of 1,500 shares of Ashfaq Textile Mills Limited

Karachi, Ashfaq Textile Mills Limited informed Pakistan Stock Exchange about transaction of shares of the company. 1,500 shares @ Rs. 7.70 per share were bought from the market on September 01, 2022, through CDC.

Ashfaq Textile Limited was incorporated in Pakistan on January 14, 1988 as a private limited company and subsequently converted into a public limited company. The business of the Company is manufacturing and sale of textiles and rendering of sizing and conversion services.

The total numbers shares are 38,483,500. The Earnings per share is 0.43 in 2020 which was 0.10 in 2019. The Profit after Taxation is 15,095,000 in 2020 which was 3,454,000 in 2019.

Posted on

Board of directors meeting Rescheduled of Atlas Battery Limited

Karachi, Atlas Battery Limited informed Pakistan Stock Exchange that board of directors meeting of the company will be held on September 12, 2022 at Karachi. The agenda of the meeting will to consider the Quarterly Accounts for the period ended June 30, 2022 for declaration of any entitlement has been rescheduled on September 13, 2022.

Further, the company has declared the closed period from September 05, 2022 to September 13, 2022.

Atlas Battery Limited was incorporated in October 1966 and it had signed a technical collaboration agreement with Japan Storage Battery Co. Ltd., Japan in 1969 for production and sale of Japanese quality batteries in Pakistan. Atlas Battery started production in 1969.

The Company is a subsidiary of Shirazi Investments Private Limited, which holds 58.86% of issued, subscribed and paid-up capital of the Company as at June 30, 2020.

The Company manufactures a wide range of lead acid batteries suitable for passenger cars, trucks, tractors, heavy vehicles, motor cycles, construction and road-building equipment as well as stationary and industrial applications.

The numbers of shares the company has issued are 24,359,676. The Earnings per Shares in 2020 are (13.43) which was (24.32) in 2019. The Company had a loss of Rs. 327,099,000 in 2020 as compared to Rs. 592,463,000 in 2019.

Posted on

Transmission of Annual Report for the Year Ended June 30, 2022 of Pakistan Cables Limited

Karachi, Pakistan Cables Limited informed Pakistan Stock Exchange that Annual Report of the Company for the year ended June 30, 2022 have been transmitted through PUCARS and is also available on Company’s website.

Pakistan Cables Limited was incorporated in Pakistan as a private limited company on 22 April 1953 and in 1955 it was converted into a public limited company. The Company is engaged in the manufacturing of copper rods, wires, cables and conductors, aluminum extrusion profiles and PVC compounds.

The Company is listed on Pakistan Stock Exchange with the total number of Shares that are 35,577,970. The Earnings per shares of the Company (2.58) in 2020 which was 3.56 in 2019. The Profit After Taxation in 2020 is (91,786,000) which was 126,233,000 in 2019.

Posted on

Financial results of Matco Foods Limited for Year ended June 30, 2022

Karachi, Matco Foods Limited informed Pakistan Stock Exchange about the recommendations made by the board of directors in the meeting held at Karachi on September 07, 2022.

The agenda of the meeting was discussion of Unconsolidated and consolidated profit and loss account for Year ended June 30, 2022 which portrayed a profit of Rs. 422,415,968 and Rs. 448,788,317 with earnings per share 3.45 and 3.67 basic and diluted respectively.

Further, nil payment of cash dividend, bonus shares and right shares was agreed.

Furthermore, the share transfer books of the company will remain closed from October 17, 2022 to October 24, 2022 (both days inclusive).

Matco Foods Limited was incorporated as a private limited company. The principal activity of the Company is to carry out the business of processing, export of rice, rice glucose, rice protein and trade of biscuits, pink salt, bran oil, masala and kheer.

The total numbers of shares are 122,400,698. The Earnings per share is 1.24 in 2020 which was 3.38 in 2019. The Profit after taxation of the Company is 151,928,000 in 2020 which was 413,836,000 in 2019.

Posted on

Resignation of Chief Financial Officer of Next Capital Limited

Karachi, Next Capital Limited informed Pakistan Stock Exchange that Miss. Sana Quadri has ceased to be the Chief Financial Officer of the company. They shall intimate new appointment in the due course.

Next Capital Limited was incorporated as a public limited company in Pakistan on 14 December 2009. The company is principally engaged in brokerage of shares, stocks, equity and debt securities, commodities, forex and other financial instruments and corporate finance services. Further, the Company is engaged in trading in equity and debt securities on its own account through ready, spot and forward counters of the stock exchange.

The total numbers of shares are 49,500,000. The Earnings per share is 0.40 in 2020 which was 0.12 in 2019. The Profit after Taxation of the Company is 17,794,000 in 2020 which was 5,307,000 in 2019.

Posted on

Financial results of Panther Tyres Limited for Year ended June 30, 2022

Karachi, Panther Tyres Limited informed Pakistan Stock Exchange about the recommendations made by the board of directors in the meeting held at Lahore on September 07, 2022.

The agenda of the meeting was discussion of profit and loss account for Year ended June 30, 2022 which portrayed a profit of Rs. 420,305,168 with earnings per share 2.50 basic and diluted respectively.

Further, nil payment of cash dividend, bonus shares and right shares was agreed.

Furthermore, the share transfer books of the company will remain closed from October 19, 2022 to October 25, 2022 (both days inclusive).

Panther Tyres Limited is in the tyres and tubes industry of Pakistan. Apart from its main business, the Company has also ventured into trading business of automobile spare parts and lubricants.

The total numbers of shares are 140,000,000. The Earnings per share is 7.06 in 2021 which was 2.50 in 2020. The Profit after taxation is 851,262,000 in 2021 which was 251,827,000 in 2020.

Posted on

Transaction of 42,321,053 shares of Cordoba Logistics & Ventures Limited

Karachi, Cordoba Logistics & Ventures Limited informed Pakistan Stock Exchange about transaction of shares of the company. 37,710,941 shares @ Rs. 10.00 per share were Right on September 05, 2022, 1,130 shares @ Rs. 10.00 per share were Right on September 05, 2022, 1,130 shares @ Rs. 10.00 per share were Right on September 05, 2022, 1,130 shares @ Rs. 10.00 per share were Right on September 05, 2022, 1,130 shares @ Rs. 10.00 per share were Right on September 05, 2022, 1,130 shares @ Rs. 10.00 per share were Right on September 05, 2022, 24,881 shares @ Rs. 10.00 per share were Right on September 05, 2022, 2,227,321 shares @ Rs. 10.00 per share were Right on September 05, 2022, 1,201,130 shares @ Rs. 10.00 per share were Right on September 05, 2022 and 1,150,000 shares @ Rs. 10.00 per share were Right on September 05, 2022 through CDC.

Cordoba Logistics & Ventures Limited, formerly Mian Textile Industries Limited, was incorporated in Pakistan on December 01, 1986 as a Public Limited Company under the Companies Ordinance, 1984. The company was principally engaged in the business of manufacturing, sale and export of textile products.

Posted on

Transaction of 236,783 shares of Crescent Cotton Mills Limited

Karachi, Crescent Cotton Mills Limited informed Pakistan Stock Exchange about transaction of shares of the company. 114,863 shares @ Rs. 35.90 per share were bought from the market on September 06, 2022, 56,500 shares @ Rs. 36.00 per share were bought from the market on September 06, 2022 and 65,420 shares @ Rs. 36..00 per share were bought from the market on September 06, 2022 through CDC.

The Crescent Cotton Mills Limited is a public limited company incorporated in March, 1959 in Pakistan. The company is engaged in the business of textile manufacturing comprising of spinning, combing, weaving, dyeing, bleaching, printing, stitching, buying, selling and otherwise dealing in yarn, cloth and other goods and fabrics made from raw cotton and synthetic fiber and to generate, accumulate, distribute, supply and sale of electricity.

The total shares of the Company are 80,000,000. The Earnings per share 0.42 in 2020 which was 2.98 in 2019. The Profit after Taxation is 33,599,000 in 2020 which was 238,589,000 in 2019.

Posted on

Material Information of Otsuka Pakistan Limited for Year ended June 30, 2022

Karachi, Otsuka Pakistan Limited informed Pakistan Stock Exchange that the Board of Directors of the company held their meeting on September 06, 2022, to consider and decide to transfer a sum of Rs. 150 million to the general reserve of the company from the profits for the year ended June 30, 2022.

Otsuka Pakistan Limited was incorporated in Pakistan as a public limited company and commenced commercial production of Intravenous Solutions in September 1989 at its factory in Hub, Baluchistan.

The Company is engaged in the manufacturing, marketing and distribution of intravenous infusions and trading in pharmaceutical products, nutritional foods and medical equipment. The Company is an indirect subsidiary of Otsuka Pharmaceutical Company Limited, Japan. Therapeutic Drugs are Otsuka Pakistan’s second line of business; currently consist of Pletaal and Mucosta which are being imported in finished form from Korea.

The total numbers of shares are 12,100,000. The Earnings per share is 7.53 in 2020 which was (14.49) in 2019. The Profit after Taxation is 91,066,000 in 2020 which was 175,348,000 in 2019.

Posted on

Financial results of Bestway Cement Limited for Year ended June 30, 2022

Karachi, Bestway Cement Limited informed Pakistan Stock Exchange about the recommendations made by the board of directors in the meeting held at Islamabad on September 06, 2022.

The agenda of the meeting was discussion of profit and loss account for Year ended June 30, 2022 which portrayed a profit of Rs. 10,239,086 with earnings per share 17.17 basic and diluted respectively.

Further, 120% payment of cash dividend, bonus shares and right shares was agreed.

Furthermore, the share transfer books of the company will remain closed from October 01, 2022 to October 07, 2022 (both days inclusive).

Bestway Cement Limited is a Public Limited Company incorporated in Pakistan on December 22, 1993. The Company is principally engaged in the production and sale of Cement, as it is a part of the Cement & Concrete Product Manufacturing Industry.

The Company is a subsidiary of Bestway (Holdings) Limited, U.K, which holds 56.43% shares in the Company. Bestway (Holdings) Limited is a wholly owned subsidiary of Bestway Group Limited, U.K.

The Shares of the Company are quoted on Pakistan Stock Exchange and used the symbol “BWCL” for the shares of the Company in PSX.

The total number of shares the company has introduced are 596,252,783. The Earning per share is 0.08 in 2020 which was 16.93 in 2019. Their Profit after Taxation is 49,252,000 in 2020 which was 10,097,285,000 in 2019.